Intuition and pharmaceutical research: The case of AstraZeneca

European Journal of Innovation Management

Volumn 7, Issue 4, 2004, Pages 267-279

  Sundgren, Mats ^a   Styhre, Alexander ^a  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Design and development; Drugs; Intuition; Organizational innovation; Pharmaceuticals industry

Indexed keywords

EID: 84986031683     PISSN: 14601060     EISSN: None     Source Type: Journal    
DOI: 10.1108/14601060410565029     Document Type: Article

References (77)

1. Agor, W. (1989), Intuition in Organizations: Leading and Managing Productively, Sage, Newbury Park, CA.
2. Amabile, T.A. (1996), Creativity in Context: Update to the Social Psychology of Creativity, Westview, Boulder, CO.
3. Andriopoulos, C. (2001), “Determinants of organizational creativity: a literature review”, Management Decision, Vol. 39 No. 10, pp. 834-40.
4. Ansell Pearson, K. (2002), Philosophy and the Adventures of the Virtual: Bergson and the Time of Life, Routledge, London and New York, NY.
5. Bachelard, G. (1964), The Poetics of Space, trans. by Jolas, M., Beacon Press, Boston, MA.
6. Bachelard, G. (1984), The New Scientific Spirit, Beacon Press, Boston, MA.
7. Bechara, A., Damasio, H., Tranel, D. and Damasio, A.R. (1997), “Deciding advantageously before knowing the advantageous strategy”, Science, Vol. 275, pp. 1293-5.
8. Bergson, H. (1992), The Creative Mind: An Introduction to Metaphysics, Citadel Press, New York, NY.
9. Bergson, H. (1999), An Introduction to Metaphysics, Hackett, Indianapolis, IN.
10. Boden, M. (1996), Dimensions of Creativity, Bradford Books, London.
11. Boje, D.M. (1991), “The storytelling organization: a study of story performance in an office supply firm”, Administrative Science Quarterly, Vol. 36 No. 1, pp. 106-26.
12. Bruner, J. (1986), Actual Minds, Possible Worlds, Harvard University Press, Cambridge, MA.
13. Bryman, A. (2000), “Telling technological tales”, Organization, Vol. 7 No. 3, pp. 455-75.
14. Cardinal, L.B. (2001), “Technological innovation in the pharmaceutical industry: the use of organizational control in managing research and development”, Organization Science, Vol. 12 No. 1, pp. 19-36.
15. Carlson, A. (2003), personal interview, January.
16. Czarniawska, B. (1998), A Narrative Approach to Organization Studies, Sage, Thousand Oaks, CA, London and New Delhi.
17. Deleuze, G. and Guattari, F. (1995), What Is Philosophy?, Verso, London.
18. Dorabje, S., Lumley, C.E. and Cartwright, S. (1998), “Culture, innovation and successful development of new medicines – an exploratory study of the pharmaceutical industry”, Leadership & Organization Development Journal, Vol. 19 No. 4, pp. 199-210.
19. Drazin, R., Glynn, M.A. and Kazanjian, R.K. (1999), “Multilevel theorizing about creativity in organizations: a sense-making perspective”, Academy of Management Review, Vol. 24 No. 2, pp. 286-307.
20. Ekvall, G. and Ryhammar, L. (1999), “The creative climate: its determinants and effects at a Swedish university”, Creativity Research Journal, Vol. 12 No. 4, pp. 303-10.
21. Eysenck, H.J. (1996), “The measurement of creativity”, in Boden, M.A. (Ed.), Dimensions of Creativity, Bradford Books, London.
22. Ford, C.M. (1995a), “Creativity is a mystery”, in Ford, C.M. and Gioia, D.A. (Eds), Creative Action in Organizations: Ivory Tower Visions and Real World Voices, Sage, Thousand Oaks, CA, pp. 12-53.
23. Ford, C.M. (1995b), “A multi-domain model of creative action taking”, in Ford, C.M. and Gioia, D.A. (Eds), Creative Action in Organizations: Ivory Tower Visions and Real World Voices, Sage, Thousand Oaks, CA, pp. 330-53.
24. Ford, C. (2000), “Creative developments in creative theory”, Academy of Management Review, Vol. 25 No. 2, pp. 284-7.
25. Ford, C.M. and Gioia, D.A. (2000), “Factors influencing creativity in the domain of managerial decision making”, Journal of Management, Vol. 26 No. 4, pp. 705-32.
26. Gabriel, Y. (2000), Storytelling in Organizations: Facts, Fictions, and Fantasies, Oxford University Press, Oxford.
27. Gephart, R.P. Jr (1996), “Postmodernism and the future history of management”, Journal of Management History, Vol. 2 No. 3, pp. 90-6.
28. Gioia, D.A. (1995), “Contrasts and convergences in creativity”, in Ford, C.M. and Gioia, D.A. (Eds), Creative Action in Organizations: Ivory Tower Visions and Real World Voices, Sage, Thousand Oaks, CA, pp. 317-29.
29. Grint, K. (1997), Fuzzy Management: Contemporary Ideas and Practices at Work, Oxford University Press, Oxford.
30. Grosz, E. (2001), Architecture from the Outside: Essays on Virtual and Real Spaces, The MIT Press, Cambridge, MA.
31. Habermas, J. (1968), Knowledge and Human Interest, Heinemann, London.
32. Heppard, K.A. and Blasick, J. (2000), “The pharmaceutical industry 1970-1995”, in Huff, A.S. and Huff, J.O. (Eds), When Firms Change Direction, Oxford University Press, Oxford.
33. Horrobin, D.F. (2001), “Innovation in the pharmaceutical industry”, Journal of the Royal Society of Medicine, Vol. 93, pp. 341-5.
34. Horrobin, D.F. (2002), “Effective clinical innovation: an ethical imperative”, Lancet, Vol. 359, pp. 1857-8.
35. Humphreys, M. and Brown, A.D. (2002), “Narratives of organizational identity and identification. A case study of hegemony and resistance”, Organization Studies, Vol. 23 No. 3, pp. 421-47.
36. Jeffcut, P. (2000), “Management and the creative industries”, Studies in Cultures, Organizations and Societies, Vol. 6, pp. 123-7.
37. Knorr Cetina, K. (1999), Epistemic Cultures: How Sciences Make Knowledge, Harvard University Press, Cambridge, MA.
38. Kolakowski, L. (1985), Bergson, Oxford University Press, Oxford and New York, NY.
39. Kvale, S. (1996), InterViewing, Sage, London.
40. Latour, B. and Woolgar, S. (1979), Laboratory Life: The Construction of Scientific Facts, Princeton University Press, Princeton, NJ.
41. Leonard, D. and Sensiper, S. (1998), “The role of tacit knowledge in group innovation”, California Management Review, Vol. 40 No. 3, pp. 112-30.
42. Lesko, J.L., Rowland, M., Peck, C.C. and Blaschke, T.F. (2000), “Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans”, Pharmaceutical Research, Vol. 17 No. 11, pp. 1335-41.
43. Linstead, S. (2002), “Organization as reply: Henri Bergson and causal organization theory”, Organization, Vol. 9 No. 1, pp. 95-111.
44. Lynch, M. (1985), Art and Artifact in Laboratory Science. A Study of Shop Work and Shop Talk in a Research Laboratory, Routledge & Kegan Paul, London.
45. Madjar, N., Oldham, G.R. and Pratt, M.G. (2002), “There's no place like home? The contributions of work and non-work creativity support to employees' creative performance”, Academy of Management Journal, Vol. 45 No. 4, pp. 757-67.
46. Massumi, B. (2002), Parables of the Virtual: Movement, Affect, Sensation, Duke University Press, Durham, NC and London.
47. Moore, F.C.T. (1996), Bergson: Thinking Backwards, Cambridge University Press, Cambridge.
48. Mullarkey, J. (1999), Bergson and Philosophy, Edinburgh University Press, Edinburgh.
49. Mumford, M.D., Scott, G.M., Gaddis, B. and Strange, J.M. (2002), “Leading creative people: orchestrating expertise and relationships”, Leadership Quarterly, Vol. 13 No. 6, pp. 705-50.
50. Nelson, R.R. (2003), “On the uneven evolution of human know-how”, Research Policy, Vol. 32, pp. 909-22.
51. Nightingale, P. (1998), “A cognitive model of innovation”, Research Policy, Vol. 27 No. 7, pp. 689-709.
52. Nightingale, P. (2003), “If Nelson and Winter are only half right about tacit knowledge, which half? A Searlean critique of codification”, Industrial and Corporate Change, Vol. 12 No. 2, pp. 149-83.
53. Orr, J.E. (1996), Talking about Machines: An Ethnography of a Modern Job, Cornell University Press, Ithaca, NY and London.
54. Pickering, A. (1995), The Mangle of Practice: Time, Agency, and Science, The University of Chicago Press, Chicago, IL and London.
55. Pisano, G.P. (1997), The Development Factory: Unlocking the Potential of Process Innovation, Harvard Business School Press, Boston, MA.
56. Policastro, E. (1995), “Creative intuition: an integrative review”, Creative Research Journal, Vol. 8 No. 2, pp. 99-113.
57. Policastro, E. (1999), “Intuition”, in Runco, M.A. and Pritzker, S.R. (Eds), Encyclopaedia of Creativity, Academic Press, London, pp. 89-91.
58. Roberts, P.W. (1999), “Product innovation, product-market competition and persistent profitability in the US pharmaceutical industry”, Strategic Management Journal, Vol. 20 No. 7, pp. 655-70.
59. Roberts, R. (1998), “Managing innovation: the pursuit of competitive advantage and the design of innovation intense environments”, Research Policy, Vol. 27 No. 2, pp. 159-75.
60. Saviotti, P.P. (1998), “On the dynamics of appropriability, of tacit and of codified knowledge”, Research Policy, Vol. 26 No. 7-8, pp. 843-56.
61. Schmid, E.F. and Smith, D.A. (2002a), “Discovery, innovation and the cyclical nature of the pharmaceutical business”, Drug Discovery Today, Vol. 7 No. 10, pp. 563-8.
62. Schmid, E.F. and Smith, D.A. (2002b), “Should scientific innovation be managed?”, Drug Discovery Today, Vol. 7 No. 18, pp. 941-5.
63. Silverman, D. (1993), Interpreting Qualitative Data, Sage, London.
64. Strauss, A.L. and Corbin, J. (1990), Basics of Qualitative Research, Sage, London.
65. Strauss, A. and Corbin, J. (1994), “Grounded theory methodology: an overview”, in Denzin, N.K. and Lincoln, Y.S. (Eds), Handbook of Qualitative Research, Sage, London.
66. Styhre, A. (2002), Understanding Knowledge Management – Critical and Postmodern Perspectives, Copenhagen Business School Press: Liber, Copenhagen.
67. Sundgren, M. and Styhre, A. (2003a), “Creativity a volatile key of success: creativity in new drug development”, Creativity and Innovation Management, Vol. 12 No. 3, pp. 145-61.
68. Sundgren, M. and Styhre, A. (2003b), “Managing organizational creativity”, in Adler, N., Shani, A.B. and Styhre, A. (Eds), Collaborative Research in Organizations, Sage, Thousand Oaks, CA, pp. 237-53.
69. Thomke, S. and Kuemmerle, W. (2002), “Asset accumulation, interdependence and technological change: evidence for pharmaceutical industry”, Strategic Management Journal, Vol. 23 No. 7, pp. 619-35.
70. Tranter, D. (2000), “Evolving to reflect the modern industrial life-science environment”, Pharmaceutical Science and Technology Today, Vol. 3 No. 12, pp. 399-400.
71. Whitehead, A.N. (1968), Modes of Thought, Free Press, New York, NY.
72. Wilson, T.D. and Schooler, J.W. (1991), “Thinking too much: introspection can reduce the quality of preference and decision making”, Journal of Personality and Social Psychology, Vol. 60, pp. 181-92.
73. Wood, M. (2002), “Mind the gap? A processual reconsideration of organizational knowledge”, Organization, Vol. 9 No. 1, pp. 151-71.
74. Woodman, R.W., Sawyer, J.E. and Griffin, R.W. (1993), “Toward a theory of organizational creativity”, Academy of Management Review, Vol. 18 No. 2, pp. 293-321.
75. Yeoh, P. and Roth, K. (1999), “An empirical analysis of sustained advantage in the US pharmaceutical industry: impact of firm resources and capabilities”, Strategic Management Journal, Vol. 20 No. 7, pp. 637-53.
76. Zivin, J.A. (2000), “Understanding clinical trials”, Scientific American, April, pp. 49-55.
77. Henderson, R. and Cockburn, I. (1994), “Measuring competence? Exploring firm effects in pharmceutical research”, Strategic Management Journal, Vol. 15, pp. 63-84.